These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 5132112)

  • 1. L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro.
    Rivera-Calimlim L; Morgan JP; Dujovne CA; Bianchine JR; Lasagna L
    Biochem Pharmacol; 1971 Nov; 20(11):3051-7. PubMed ID: 5132112
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602).
    Bakke OM; Scheline RR
    J Pharm Pharmacol; 1974 May; 26(5):377-9. PubMed ID: 4152920
    [No Abstract]   [Full Text] [Related]  

  • 3. Absorption and metabolism of L-dopa by the human stomach.
    Rivera-Calimlim L; Dujovne CA; Morgan JP; Lasagna L; Bianchine JR
    Eur J Clin Invest; 1971 May; 1(5):313-20. PubMed ID: 5558777
    [No Abstract]   [Full Text] [Related]  

  • 4. Histidine decarboxylase and DOPA decarboxylase in the stomach of the developing rat.
    Aures D; Håkanson R
    Experientia; 1968 Jul; 24(7):666-7. PubMed ID: 5705217
    [No Abstract]   [Full Text] [Related]  

  • 5. Histidine decarboxylase in the stomach of the rat.
    Radwan AG; West GB
    J Pharm Pharmacol; 1967 May; 19(5):305-12. PubMed ID: 4382402
    [No Abstract]   [Full Text] [Related]  

  • 6. Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase.
    Bartholini G; Pletscher A
    J Pharmacol Exp Ther; 1968 May; 161(1):14-20. PubMed ID: 5648492
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of pyridoxal phosphate and L-dopapyridoxal phosphate on DOPA decarboxylase activity.
    Tran N
    Experientia; 1972 Sep; 28(9):1021-2. PubMed ID: 4665286
    [No Abstract]   [Full Text] [Related]  

  • 8. New pathway for metabolism of dopa.
    O'Leary MH; Baughn RL
    Nature; 1975 Jan; 253(5486):52-3. PubMed ID: 1167399
    [No Abstract]   [Full Text] [Related]  

  • 9. The enzymatic decarboxylation of DOPA in human liver homogenates.
    Vogel WH; Snyder R; Hare TA
    Proc Soc Exp Biol Med; 1970 Jun; 134(2):477-81. PubMed ID: 5310151
    [No Abstract]   [Full Text] [Related]  

  • 10. Decarboxylation of 3,4-dihydroxyphenylalanine by oxyhemoglobin.
    Yamabe H; Lovenberg W
    Biochem Biophys Res Commun; 1972 May; 47(4):733-9. PubMed ID: 5063594
    [No Abstract]   [Full Text] [Related]  

  • 11. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition.
    Sandler M; Johnson RD; Ruthven CR; Reid JL; Calne DB
    Nature; 1974 Feb; 247(5440):364-6. PubMed ID: 4817854
    [No Abstract]   [Full Text] [Related]  

  • 12. Decline of histidine decarboxylase activity and histamine levels in rat stomach after reserpine.
    Isaac L; Cho AK; Beaven MA
    Biochem Pharmacol; 1971 Jul; 20(7):1453-61. PubMed ID: 5163084
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 14. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphologic and biochemical changes in the gut after chronic treatment with L-dopa.
    Rivera-Calimlim L; Bosmann HB; Penney DP; Lasagna L
    J Pharmacol Exp Ther; 1973 Feb; 184(2):440-8. PubMed ID: 4734582
    [No Abstract]   [Full Text] [Related]  

  • 16. The influence of L-DOPA perfusion concentrations and peripheral decarboxylase inhibition on dopa accumulation and decarboxylation in isolated perfused rat brains.
    Horst WD; Bautz G; Renyi E; Spirt N
    Neuropharmacology; 1973 Dec; 12(12):1145-51. PubMed ID: 4782694
    [No Abstract]   [Full Text] [Related]  

  • 17. Action of actinomycin D on gastro-intestinal glucose uptake and on the glucose effect upon rat liver tyrosine transaminase activity.
    Shanoune J; Chambaut AM
    Biochim Biophys Acta; 1971 Oct; 252(1):212-6. PubMed ID: 4401031
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of analogs of phenylalanine and tryptophan on kinetics of DOPA decarboxylase in rat brain.
    De Ropp RS; Furst A
    Brain Res; 1966 Oct; 2(4):323-32. PubMed ID: 5298124
    [No Abstract]   [Full Text] [Related]  

  • 19. Distribution of DOPA-2- 14 C in relation to DOPA-1- 14 C (carboxyl- 14 C-labelled DOPA) in mice before and after inhibition of DOPA-decarboxylase, studied by whole-body autoradiography.
    Tjälve H; Ullberg S
    Arch Int Pharmacodyn Ther; 1972 Oct; 199(2):376-88. PubMed ID: 4627124
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease.
    Bianchine JR; Calimlim LR; Morgan JP; Dujuvne CA; Lasagna L
    Ann N Y Acad Sci; 1971 Jul; 179():126-40. PubMed ID: 5285373
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.